Panacea Biotec profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Returns
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.6%−0.6%−1.0%−0.1%−4.0%
−0.6%−0.6%−0.7%−0.1%−2.2%
−4.1%−4.1%−6.6%−6.1%−14.3%
−3.3%−4.7%−7.9%−2.9%−6.8%
Margins
0.3%−0.7%−4.6%−3.6%−21.3%
−5.9%−5.9%−10.9%−10.2%−29.8%
—28.5%4,937.5%80.9%—
−1.5%−1.2%−1.4%0.3%2.8%
−1.3%−1.1%−1.6%−0.3%−7.3%
−1.1%−0.8%−1.5%−0.2%−7.3%
−5.9%−5.9%−13.9%−13.9%−101.0%
Additional
13.9%2.9%−9.7%201.4%363.7%
−0.6%−0.6%−1.0%−0.1%−4.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,017 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-3.99-0.14-1.00-0.64-0.64
Return on Assets-2.21-0.12-0.69-0.56-0.56
Return on Capital Employed-14.25-6.06-6.55-4.11-4.11
Return on Invested Capital-6.79-2.94-7.91-4.67-3.33
Margins
EBITDA Margin-21.30-3.59-4.63-0.730.33
Operating Margin-29.80-10.15-10.86-5.90-5.90
Incremental Operating Margin—80.944,937.5028.51—
Pretax Margin2.780.26-1.42-1.15-1.54
Net Income Margin-7.34-0.27-1.56-1.12-1.33
Net Income to Common Margin-7.34-0.21-1.50-0.84-1.06
FCF Margin-100.97-13.92-13.89-5.85-5.85
Additional
Effective Tax Rate363.67201.35-9.692.8513.90
Sustainable Growth Rate-3.99-0.14-1.00-0.64-0.64
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.